BeOne Medicines Ltd. (ONC)
354.47
+4.34
(+1.24%)
USD |
NASDAQ |
Oct 09, 16:00
354.12
-0.35
(-0.10%)
Pre-Market: 20:00
BeOne Medicines Free Cash Flow : 1.333B for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.333B |
| March 31, 2026 | 1.098B |
| December 31, 2025 | 924.18M |
| September 30, 2025 | 525.67M |
| June 30, 2025 | 225.30M |
| March 31, 2025 | -180.47M |
| December 31, 2024 | -637.97M |
| September 30, 2024 | -1.009B |
| June 30, 2024 | -1.309B |
| March 31, 2024 | -1.519B |
| December 31, 2023 | -1.739B |
| September 30, 2023 | -1.790B |
| June 30, 2023 | -2.215B |
| March 31, 2023 | -2.228B |
| December 31, 2022 | -1.821B |
| September 30, 2022 | -2.048B |
| June 30, 2022 | -1.942B |
| March 31, 2022 | -1.972B |
| December 31, 2021 | -1.607B |
| September 30, 2021 | -1.308B |
| Date | Value |
|---|---|
| June 30, 2021 | -1.118B |
| March 31, 2021 | -954.79M |
| December 31, 2020 | -1.401B |
| September 30, 2020 | -1.317B |
| June 30, 2020 | -1.238B |
| March 31, 2020 | -1.010B |
| December 31, 2019 | -839.88M |
| September 30, 2019 | -766.77M |
| June 30, 2019 | -637.96M |
| March 31, 2019 | -698.16M |
| December 31, 2018 | -618.55M |
| September 30, 2018 | -334.20M |
| June 30, 2018 | -179.09M |
| March 31, 2018 | -119.16M |
| December 31, 2017 | -45.75M |
| September 30, 2017 | -154.76M |
| June 30, 2017 | -173.76M |
| March 31, 2017 | -130.65M |
| December 31, 2016 | -113.02M |
| September 30, 2016 | -99.00M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Basilea Pharmaceutica AG | 71.34M |
| Santhera Pharmaceuticals Holding AG | -0.8494M |
| AC Immune SA | -- |
| CRISPR Therapeutics AG | -371.32M |
| Idorsia Ltd. | -172.44M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 463.60M |
| Cash from Investing (Quarterly) | -49.41M |
| Cash from Financing (Quarterly) | -6.128M |
| Free Cash Flow Per Share (Quarterly) | 3.766 |
| Free Cash Flow to Equity (Quarterly) | 439.88M |
| Free Cash Flow to Firm (Quarterly) | 466.30M |
| Free Cash Flow Yield | 3.26% |